Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results.
Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19. Revenue surged 36% to $5.116 billion, beating Wall Street’s estimate of $4.542 billion.
“This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “Our pipeline of about 50 product candidates is rapidly advancing. We expect an FDA decision for cemdisiran in generalized myasthenia gravis next month; our Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity continue to advance; and we have generated encouraging early data in MASH, POTS, and ovarian cancer. Finally, we expanded our alliance with Sanofi to include four Regeneron-invented, next-generation, long-acting antibodies designed to build on the success of Dupixent.”
Regeneron Pharmaceuticals shares closed at $927.89 on Friday.
These analysts made changes to their price targets on Regeneron Pharmaceuticals following earnings announcement.
- B of A Securities analyst Tazeen Ahmad maintained the stock with a Buy and raised the price target from $908 to $1,030.
- Baird analyst Brian Skorney maintained the stock with a Neutral and boosted the price target from $761 to $875.
- Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $795 to $980.
- Canaccord Genuity analyst John Newman maintained the stock with a Buy and raised the price target from $922 to $1,175.
Considering buying REGN stock? Here’s what analysts think:
Photo via Shutterstock